Skip to content

Evaluation of safety and effects of consuming ginger gummies on dysmenorrhea in volunteers

Evaluation of safety and effects of consuming ginger gummies on dysmenorrhea in volunteers.

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240905003
Enrollment
63
Registered
2024-09-05
Start date
2025-07-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Women Healthy condition without severe illness, and will during dysmenorrhea. Ginger, Functional ingredient, Functional food, Healthy women

Interventions

The group consume gummies without ginger extract 1 serving/day for 6 weeks.,The group consume gummies containing ginger extract 250 mg/serving/day for 6 weeks.,The group consume gummies containing gin
Placebo,Ginger Gummies 250 mg/serving,Ginger Gummies 500 mg/serving

Sponsors

Program Management Unit Competitiveness (PMUC)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Healthy female volunteers aged 18-35 years 2. Have dysmenorrhea symptoms in the past 6 months, have a pain score assessed by the 11-point numerical rating scale (NRS) in the range of 4 less than pain score less than 11 3. Have had a regular menstrual period in the past 3 months 4. Can communicate, read and write in Thai language.

Exclusion criteria

Exclusion criteria: 1. Have chronic diseases that require continuous medication, such as cardiovascular disease or blood clot obstruction, lung disease, thyroid disease, adrenal gland, pituitary gland, cancer, diabetes, allergies, liver disease, chronic kidney disease (estimate GFR less than 60 mL/min/1.73m2), and have a history of brain injury. 2. Take cholesterol-lowering drugs, blood sugar-lowering drugs Antihypertensive drugs or drugs that interfere with platelet function, such as aspirin and nonsteroidal anti-inflammatory drugs 3. Taking general antibiotics or Paracetamol, which have pain-reducing effects 4. Taking birth control pills or hormones or calcium or vitamin D supplements or herbs regularly 5. Being pregnant or having a history of uterine abnormalities (fibroids, polyps, endometrial hypertrophy, and endometriosis) or ovarian abnormalities 6. Having given birth less than 32 weeks ago 7. Having abnormal vaginal discharge or abnormal cervical cells 8. Having a history of hysterectomy or ovarian surgery (Hysterectomy and/or Oophorectomy) 9. Having depression or anxiety or high stress 10. Drinking more than 5 alcoholic drinks (1000 ml) per day 11. Smoking more than 10 cigarettes per day 12. Being involved in other human research projects

Design outcomes

Primary

MeasureTime frame
Assessing pain score Baseline, week 6th Using Numerical Rating Scale (NRS)

Secondary

MeasureTime frame
Demorgraphic data Baseline, week 6th Vital sign, Electrocardiogram, Body Mass Index (BMI), Body Composition, Body Composition Analyzer, Anthropometry,Safety parameters Baseline, week 6th Hematology, Blood biochemical markers, Blood electrolytes by Hospital Laboratory,Oxidative stress markers (MDA, SOD, CAT, GPx, 8-OHDG, iNOS, Nrf2) Baseline, week 6th ELISA kis or Assay kits, HHPHP laboratory,Inflammatory markers (Il-6, NF-KB, TNF-alpha, COX2, PGF2alpha, PGE, PGF2alpha/PGE ratio Baseline, week 6th ELISA kis, HHPHP laboratory,Assessing Depression Anxiety Stress Baseline, week 6th Depression Anxiety Stress Scales (DASS-21)

Countries

Thailand

Contacts

Public ContactWeerapon Sangartit

Faculty of Medicine, Khon Kaen University

weerasan@kku.ac.th66815443260

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026